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Open access under CC BY licenseere we describe a versatile high-throughput expression system that permits genome-wide screening of
pe 1 membrane and secreted proteins for interactions with glycans and proteins using both cell-
pressed and soluble forms of the expressed proteins. Based on Gateway cloning methodology, we have
gineered a destination vector that directs expression of enhanced green ﬂuorescent protein (EGFP)-
gged proteins at the cell surface via a glycosylphosphatidylinositol tail. The EGFP fusion proteins can
en be cleaved with PreScission protease to release soluble forms of proteins that can be optionally bio-
nylated. We demonstrate the utility of this cloning and expression system for selected low-afﬁnity
embrane lectins from the siglec family of sialic acid-binding immunoglobulin-like lectins, for the gly-
saminoglycan-binding proteins FGF-1 and BACE, and for the heterotypic adhesion molecules JAM-B
d JAM-C. Cell-expressed proteins can be evaluated for glycan interactions using polyvalent soluble gly-
n probes and for protein interactions using either cells or soluble proteins. Following cleavage from the
ll surface, proteins were complexed in solution and sufﬁcient avidity was achieved to measure weak
rotein–glycan and weak protein–protein interactions using glycan arrays and surface plasmon reso-
ance, respectively.
 2011 Elsevier Inc.Open access under CC BY license.4si
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pCellular recognition by membrane and secreted proteins com-
only involves both protein–protein and protein–glycan interac-
ons, with the latter being mediated by lectin-like proteins [1].
rotein–glycan interactions are important in regulating a wide
riety of physiological functions, especially in the nervous and
mune systems, and their dysregulation can contribute signiﬁ-
ntly to human pathologies [2–4]. In mammals, a growing num-
er of lectin-like receptors and secreted proteins are being
entiﬁed, and many have been assigned to discrete families based
n sequence similarity, including C-type lectins, galectins, ander).
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.glecs (sialic acid-binding immunoglobulin [Ig]-like lectins)
,5]. It is likely that many other proteins mediate biologically
portant glycan recognition functions, but a systematic approach
required to screen membrane and secreted proteins for their abil-
y to interact with glycans. The recent availability of publicly acces-
ble mammalian gene collections [6] and the development of glycan
ray technologies [7–10] have opened up the possibility of system-
ically screening expressed proteins of interest against hundreds of
ifferent glycan structures and deﬁning novel lectin-like activities of
roteins.4 Abbreviations used: Ig, immunoglobulin; siglec, sialic acid-binding Ig-like lectin;
I, glycosylphosphatidylinositol; PP, PreScission protease; FGF-1, ﬁbroblast growth
ctor 1; BACE, b-site APP-cleaving enzyme; JAM, junctional adhesion molecule; EGFP,
hanced green ﬂuorescent protein; GFP, green ﬂuorescent protein; PCR, polymerase
ain reaction; cDNA, complementary DNA; Int, integrase; IHF, integration host
ctor; Xis, excisionase; CHO, Chinese hamster ovary; FCS, fetal calf serum; Ab,
tibody; APC, allophycocyanin; PBS, phosphate-buffered saline; EDTA, ethylenedi-
inetetraacetic acid; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel elec-
ophoresis; PAA, polyacrylamide; NGL, neoglycolipid; BSA, bovine serum albumin;
PS, gamma aminopropylsilane; ELISA, enzyme-linked immunosorbent assay.
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ten depend on clustering of both the receptor and ligand to medi-
ate high-avidity binding [11]. Protein expression strategies for
glycan array screening need to take this into account. One ap-
proach is to express proteins as preformed multimers or to engi-
neer tags that can be exploited for multimerization in solution by
using appropriate cross-linking agents. Another strategy is to ex-
press candidates on the cell surface in a format that is permissive
to ligand-induced clustering, resulting in high-avidity binding. Gly-
cosylphosphatidylinositol (GPI) anchors are a useful way to
achieve this because they are embedded in the outer leaﬂet of
the plasma membrane and can localize within discrete membrane
microdomains [12]. Because they are not tethered directly to cyto-
skeletal proteins, they are more likely to be freely diffusible and
available for ligand-induced clustering [13]. Furthermore, GPI an-
chors are able to transport proteins efﬁciently to the cell surface
[14].
Besides protein–glycan interactions, many biologically impor-
tant protein–protein interactions can also be of low afﬁnity, partic-
ularly those involved in transient and regulated interaction such as
those at the cell surface, and this is a particular feature of the im-
mune system where cellular contacts are often transient and regu-
lated [15]. Therefore, the same system that is designed for analysis
of low-afﬁnity glycan interactions can also be used to screen for
protein-dependent interactions.
Here we describe a Gateway-based cloning system [16] that al-
lows high-throughput cloning and expression of secreted and type
1 membrane proteins that can be screened for glycan- and protein-
binding properties. A particularly useful feature of this system is
that tagged proteins are initially expressed as GPI-anchored mem-
brane receptors that can then be cleaved selectively from the cell
surface using human rhinovirus 3C protease (PreScission protease
[PP]). This versatility allows proteins of interest to be screened for
molecular interactions when presented either at the cell surface or
in solution following cleavage. We demonstrate that this expres-
sion system can be used to measure weak protein–glycan and
protein–protein interactions using several well-established mem-
brane and secreted proteins, including siglecs, the heparan
sulfate-binding proteins FGF-1 (ﬁbroblast growth factor 1) and
BACE (b-site APP [amyloid precursor protein]-cleaving enzyme),
and a pair of heterotypic junctional adhesion molecules (JAMs),
JAM-B and JAM-C. The broad ﬂexibility of this high-throughput
system can be applied to genome-wide investigations of protein–
glycan and protein–protein interactions.
Materials and methods
Generation of destination vectors
The pEGFP–N1 cloning vector (BD Biosciences Clontech,
GenBank Accession No. U55762) that encodes enhanced green
ﬂuorescent protein (EGFP), a red-shifted variant of the wild-type
green ﬂuorescent protein (GFP) gene, was linearized with blunt-
end restriction enzyme SmaI. Ligations of vector with the Gateway
C1 cassette, containing the suicide ccdB box with ccdB and
chloramphenicol genes and attR sites (Invitrogen, Product No.
11828-019), were transformed into the DB3.1 Escherichia coli strain
and positive clones were selected on chloramphenicol plates.
Correct orientation of the cassette was veriﬁed by restriction
digests and sequencing, resulting in the EGFP–pDEST vector. The
GPI signal of the TRAIL receptor 3 was ampliﬁed by the polymerase
chain reaction (PCR) using a complementary DNA (cDNA) clone
kindly supplied by D. Legler [12]. PCR primer sequences used in
this study are provided in Supplementary material. The PCR
product was digested, puriﬁed, and subcloned into the BsrGI/NotI
sites of EGFP–N1. The EGFP–GPI domain was digested with AgeI/DraIII and cloned into the EGFP–pDEST vector, resulting in EGFP–
GPI–pDEST. A PP site [17] was added using a QuickChange site-di-
rected mutagenesis kit (Stratagene) to generate an EGFP–PP–GPI–
pDEST vector. A minimal 14-residue peptide tag (LNDIFEAQ-
KIEWHE) called the Avitag [18], which can be biotinylated by BirA,
was PCR ampliﬁed and cloned into the vector using the Quick-
Change site-directed mutagenesis kit together with a 7-residue lin-
ker (GSPGSPG) to generate the ﬁnal destination vector EGFP–
LNKAVI–PP–GPI–pDEST.
Generation of entry and expression clones
The signal peptides and extracellular regions from selected
cDNAs were ampliﬁed by PCR. The PCR samples were gel puriﬁed
and subjected to the BP reaction using BP Clonase mix and the
pDONOR207 entry vector (Invitrogen). BP Clonase is a proprietary
enzyme formulation containing the bacteriophage lambda recom-
bination protein Int (integrase) and the E. coli-encoded protein IHF
(integration host factor) that catalyze the in vitro recombination of
PCR products or DNA segments from clones (containing attB sites)
and a donor vector (containing attP sites) to generate entry clones.
Correct entry clones were identiﬁed by restriction digest analysis
and further used in LR reactions (Invitrogen) with the EGFP–LNK-
AVI–PP–GPI–pDEST vector to generate expression clones. LR Clon-
ase II enzyme mix contains a proprietary blend of Int, IHF, and Xis
(excisionase) enzymes that catalyze the in vitro recombination be-
tween an entry clone (containing a gene of interest ﬂanked by attL
sites) and a destination vector (containing attR sites) to generate
an expression clone. Restriction digests identiﬁed correct clones,
which were further veriﬁed by sequencing. BP and LR reactions
routinely showed at least 90% cloning efﬁciencies.
Generation of stable cell lines
Chinese hamster ovary (CHO) cells (5  106) were transfected
with expression clones by electroporation in Ham’s F12 + 20% fetal
calf serum (FCS), using a Bio-Rad electroporator and Bio-Rad 0.4-
cm cuvettes, at 260 V, 960 F, and 50 lg of DNA. Cells were cul-
tured for 2 weeks in medium containing 1.0 mg/ml neomycin
(G418 disulﬁde), and drug-resistant cells were sorted for EGFP
expression using a FACS Vantage SE cell sorter (Becton Dickinson,
Oxford, UK). Cell lines were sorted for a second or third time using
biotin anti-EGFP antibody (Ab) (Vector Labs) and streptavidin–all-
ophycocyanin (APC) staining (BD Biosciences).
Production of biotinylated soluble recombinant protein
CHO cells were grown as adherent cultures and harvested by
incubation for 10–30 min in phosphate-buffered saline (PBS) con-
taining 10 mM ethylenediaminetetraacetic acid (EDTA) at 37 C.
After washing, 6  107 cells were suspended in 300 ll of Ca2+-
and Mg2+-free Hank’s buffered salt solution containing 0.5 mM
EDTA and 1 mM dithiothreitol. PP was added at a ﬁnal concentra-
tion of 15 lg/ml. The cell suspension was incubated at 4 C for 4 h.
The cells were spun down, and the PP digestion was stopped by the
addition of the sulfhydryl blocking agent iodoacetamide (10 lM).
Recombinant proteins were analyzed by Western blotting using
5–15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) linear gradient polyacrylamide gels (Novagen) fol-
lowed by transfer to nitrocellulose membranes (Schleicher–Schu-
ell). Blots were blocked in casein solution and incubated with
biotin goat anti-GFP Ab (10 lg/ml, Vector Labs) followed by a pre-
formed complex between streptavidin and biotinylated alkaline
phosphatase (Vectastain ABC–Amp, Vector Labs). The chromogenic
substrate for alkaline phosphatase, 5-bromo-4-chloro-3-indolyl
phosphate/nitroblue tetrazolium, was provided by the DuoLuX
Table 1
Glycan composition of probes.
aPolyacrylamide conjugates, 30 kDa, with approximately 40 glycan residues and 10
biotin residues per macromolecule.
bGlycolipids with a ceramide having 36 carbon atoms [22].
cNeoglycolipids [23] prepared from reducing oligosaccharides by reductive ami-
nation with the amino lipid, 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine
[42].
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by comparing the intensity of protein bands at two dilutions with
that obtained with a GFP standard that was routinely included at 1
and 3 ng on each blot.
Biotinylation was performed with BirA according to the manu-
facturer’s guidelines (Avidity, Denver, CO, USA). Protein (250 ng)
was incubated in 50 mM D-biotin and 10,000 U of BirA at room
temperature for 1.5 h in a volume of 300 ll. Excess biotin was re-
moved by desalting into PBS using fast ultraﬁltration ﬁlter devices
(Millipore, Consett, UK). Biotin incorporation was analyzed by
Western blotting as described above except that the biotin anti-
GFP step was omitted.
Cellular binding assays
Cell binding to speciﬁc glycans attached to biotinylated poly-
acrylamide (PAA) was determined as described previously [19].
Brieﬂy, cells were detached from tissue culture ﬂasks using PBS
containing 10 mM EDTA at 37 C and treated with Vibrio cholerae
sialidase (0.05 U/ml) at 37 C for 1 h to unmask siglecs as described
before [19]. Cells were then incubated with biotinylated PAA com-
pounds [20] at 20 lg/ml for 1 h on ice followed by streptavidin–
APC (0.5 lg/ml) for 30 min prior to analysis on a FACSCalibur
system (BD Biosciences).
Cell-to-cell binding mediated by JAM-B and JAM-C was assessed
using a ﬂow cytometric assay in which CHO cells expressing each
adhesion molecule were differentially labeled with ﬂuorescent
markers and the presence of cell couples was detected by dual
ﬂuorescence. Differential labeling was achieved using the lipo-
philic carbocyanine dyes DiI and DiD (Invitrogen), which emit light
at 565 and 665 nm, respectively. Following labeling according to
the manufacturer’s guidelines, cells were washed, mixed together
in 1:1 ratio, and pelleted by centrifugation, and the pellets were
gently mixed and then incubated on ice for 1 h. After gentle resus-
pension, the extent of cell–cell binding was determined using a
FACSCalibur.
Cell binding to recombinant proteins was performed by incu-
bating 0.5  105 wild-type or transfected CHO cells with 0.8 lg/
ml biotinylated proteins for 1 h on ice. After washing, cells were
incubated with streptavidin–APC (1 lg/ml) for 30 min prior to
analysis on a FACSCalibur.
Glycan microarray analyses
Lipid-linked oligosaccharide probes (Table 1) were printed on
nitrocellulose-coated glass slides (FAST slides, Whatman) in a
dose–response format from 1 to 5 fmol/spot with a noncontact ar-
rayer (Piezorray, PerkinElmer), including Cy3 dye in the array ﬂuid
to enable postarray monitoring of the spots [21]. These were in the
form of synthetic glycolipids [22] and neoglycolipids (NGLs) de-
rived from natural oligosaccharides [23]. Binding analysis was per-
formed essentially as described previously [24]. In brief, the
arrayed slides were overlaid initially for 1 h with blocking solution
(1% [w/v] bovine serum albumin [BSA, Sigma] in 2% [v/v] Pierce
Casein Blocker solution, 10 mM Tris–HCl [pH 8.0], and 150 mM
NaCl) at ambient temperature. The slides were rinsed with block-
ing buffer and overlaid for 1.5 h with the biotinylated siglec–GFP
constructs that had been precomplexed for 1 h at 4 C with Alexa-
Fluor-647–streptavidin (Molecular Probes) (1:1, w/w) and rabbit
anti-GFP (Invitrogen) (1:6, w/w). This precomplexing condition
was selected after trials of different ratios of reactants. The
precomplexed proteins were applied onto the slides at a ﬁnal
concentration of approximately 1.5 lg/ml in blocking solution.
Incubation was for 90 min at ambient temperature, and binding
was detected by incubating with biotinylated anti-rabbit IgG
(Sigma) (1:200, v/v) in blocking solution for 1 h followed by Alexa-Fluor-647-labeled streptavidin (1 lg/ml) in blocking solution for
35 min. Slides were scanned using a GenePix 4200AL scanner
(Molecular Devices, Sunnyvale, CA, USA), and binding signals were
quantiﬁed using GenePix Pro 6.0 (Molecular Devices). Data analysis
and presentation were carried out using Microsoft Excel. The re-
sults are presented as means of ﬂuorescence intensities of dupli-
cate spots after background subtraction. The error bars represent
half of the difference between the two values.
Heparin saccharide microarray fabrication and interrogation
Saccharides from porcine mucosal heparin (Celsus Labs, Cincin-
nati, OH, USA) were generated via partial digestion with heparinase
I (IBEX Technologies, Montreal, Canada) and size exclusion chroma-
tography fractionation using the procedure described previously
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was prepared, lyophilized, and resuspended in formamide (Sigma–
Aldrich Chemie, Steinheim, Germany) supplemented with 1.5 M
betaine (Sigma–Aldrich, St. Louis,MO, USA). Saccharidemicroarrays
were fabricated onto GAPS II microarray slides (Corning, Corning,
NY, USA) from low to high concentration with spots 0.36 mm apart
using a single MicroSpot 2500 split pin and a MicroGrid TAS robot
(Genomic Solutions, Huntingdon, UK) operated at 57% humidity
and 17 C. The coupling chemistry involves nucleophilic attack of
the amine on gamma aminopropylsilane (GAPS) slides to the car-
bonyl of the heparin saccharide [27]. Spots were quality controlled
visually under a microscope, and slides were immediately micro-
wave heated (5 min at 50% power in an 850-W oven followed by
10 min cooling at room temperature in the dark) three times in suc-
cession [27]. Slides were washed with deionized water (pH 7.0),
dried using an air compressor, and stored with dessicant at room
temperature in a sealed bag until required.
Slides were blocked with 1% (w/v) BSA (Fraction V, Sigma–
Aldrich) in PBS. Arrays were then sequentially incubated with
approximately 20 nM biotinylated protein–EGFP conjugates in ﬁl-
tered physiological buffer, 1% BSA, 0.1% Tween 20 (Sigma–Aldrich),
and 1 lg/ml AlexaFluor-546-labeled streptavidin (Invitrogen) in
ﬁltered PBS, 1% BSA, and 0.05% Tween 20. Incubations were per-
formed for 1 h at room temperature using a 16-well array incuba-
tion chamber (Whatman) in a moist environment. Slides were
washed with deionized water (pH 7.0) for 5 min after each incu-
bation and dried using an air compressor.
Microarrays were scanned at 532 nm with 10 lm resolution
using a GenePix 4000A scanner (Molecular Devices) operated with
GenePix Pro 3.0 software. The photomultiplier tube intensity was
adjusted to the maximum permitted without saturation of any sig-
nals. Fluorescent intensity analysis with GenePix Pro 3.0 software
used features ﬁtted by eye to spots so that the diameter matched
that of the spot as closely as possible. Intensity valueswere exported
into Excel, and themean of the difference between themean feature
and background intensities for replicate spots was calculated.
Assessment of protein–protein interactions using Biacore
Measurement of protein–protein interactions was performed by
surface plasmon resonance using a Biacore X (Biacore, Uppsala,
Sweden). Streptavidin-coated chips were obtained from Biacore.
All experiments were performed in PBS containing 0.005% Tween
20 at pH 7.0. HCl (100 mM) was used for regeneration of the chips.
To immobilize the proteins, biotin–JAM-B–EGFP or biotin–JAM-C–
EGFP (8 lg/ml) was injected for 50 min over the surface of a
streptavidin chip at a ﬂow rate of 1 ll/min. Unbound protein was
removed from the chip by washing with buffer. A JAM/anti-GFP
Ab mixture (1:10 molar ratio) was prepared, incubated at room
temperature for 1 h to allow complex formation, and then injected
for 12 min over the surface of the JAM-B- or JAM-C-coated chip.
The solution was replaced with running buffer for 6 min, and the
chip was regenerated with HCl and used sequentially for the next
injections of JAM/anti-GFP Ab. Anti-GFP Ab only (the amount used
in the 1:10 JAM/anti-GFP Ab complex) was injected over the chip
surface as a control at a ﬂow rate of 5 ll/min. BIAevaluation soft-
ware was used for analysis of the data.
Results
High-throughput cloning and expression of type 1 membrane and
secreted proteins
The Gateway cloning system has several advantages over
conventional cloning strategies, particularly in terms of speed,
simplicity, and versatility [16]. Fig. 1A illustrates the key featuresof the system developed for high-throughput surface expression
and screening of type 1 membrane and secreted proteins for pro-
tein–glycan and protein–protein interactions. An entry clone con-
taining the leader peptide and extracellular region of interest,
corresponding to either a type 1 membrane protein or a secreted
protein, is recombined with a destination vector to generate an
expression clone. This encodes a GPI-anchored version of the pro-
tein of interest together with an EGFP tag, an Avitag biotin acceptor
peptide, and a site for PP cleavage. This versatile expression system
can be used to generate cell-bound and cleaved forms of proteins
that can be optionally biotinylated using the BirA enzyme (Fig. 1B).
To evaluate this system, we selected several well-characterized
membrane and secreted proteins known to mediate either glycan
or protein interactions. These included members of the siglec fam-
ily of sialic acid-binding Ig-like lectins, the heparan sulfate-binding
proteins FGF-1 and BACE, and the heterotypic adhesion molecule
partners JAM-B and JAM-C. These proteins bind their ligands in a
divalent cation-independent manner; therefore, binding assays
were performed using Ca2+- and Mg2+-free media. Following drug
selection and FACS sorting for EGFP expression, stably expressing
CHO cell lines could be generated for all constructs tested. Flow
cytometric analysis for total endogenous EGFP expression and sur-
face-expressed EGFP revealed diagonal scatter in dot plots, indicat-
ing efﬁcient surface expression (Fig. 2).Cell-based screens for protein–glycan interactions
To investigate whether the surface-expressed proteins could be
used to measure protein–glycan interactions, we focussed on sig-
lecs-7, -8, and -9, which are known from previous studies to have
distinct preferences for sialylated glycans [24]. Clustered siglecs
bind with high avidity to glycans presented in multimeric arrays
on PAA backbones [19,28], but when siglec-binding activity is ex-
pressed at the cell surface, it is often inhibited by cis interactions
with sialic acids [5]. Therefore, CHO cells expressing siglecs-7, -8,
and -9 were treated with sialidase to remove the cis-interacting
sialic acids and assayed for binding to PAA–glycans (Fig. 3 and Ta-
ble 1). None of the siglec-expressing CHO cells bound to lactose–
PAA used as a negative control, but selective binding was seen with
PAA–glycans known to bind each siglec, namely Sia2,8Sia (siglec-
7), 60SU-SLex (siglec-8), and SLex (siglec-9) (Fig. 3 and Table 1).
These results demonstrate the utility of the cell expression system
for screening glycan interactions of membrane proteins.Cleavage of surface-expressed proteins
To convert the GPI-anchored proteins to soluble proteins, cell
pellets expressing siglecs-7, -8, and -9 were treated with PP under
varying conditions and the amount of residual protein on the cell
surface was measured by ﬂow cytometry. PP cleaves between
Gln and Gly residues of the recognition sequence Leu-Glu-
Val-Leu-Phe-Gln-Gly-Pro [17], which was engineered into the
destination vector. PP was able to cleave up to 90% of cell sur-
face-expressed proteins within 4 h of incubation at 4 C (data not
shown). Cell viability was routinely greater than 90% under these
conditions. The soluble protein released into the supernatant was
measured by Western blotting using puriﬁed recombinant GFP as
a standard (Fig. 4A) or by enzyme-linked immunosorbent assay
(ELISA) (data not shown). By both approaches, yields of proteins
were usually between 100 and 300 ng/107 cells. Following PP treat-
ment, Western blots of soluble material probed with anti-GFP anti-
bodies showed speciﬁc bands corresponding to the expected sizes
of the cleaved proteins (Fig. 4A). Treatment of the soluble cleaved-
off proteins with BirA resulted in biotin incorporation, as shown in
Western blots probed with streptavidin conjugate (Fig. 4B).
Fig.1. Gateway-based cloning and expression system. (A) An entry clone containing the leader peptide and extracellular domain (ECD) of interest is recombined via the LR
reaction with a destination vector to generate an expression clone. This incorporates the ECD fused to EGFP, an Avitag biotin acceptor peptide, a PP cleavage site, and a GPI
signal sequence. (B) Following expression in mammalian cells, surface-presented protein can be cleaved with PP and biotinylated with BirA either at the cell surface or
following cleavage. This versatile cloning vector enables multiple assays with either cell-expressed or soluble versions of the protein of interest.
Fig. 2. Expression of EGFP fusion proteins in CHO cells measured by ﬂow cytometry. Cell surface expression of EGFP fusion proteins was measured on living cells using
biotinylated anti-GFP followed by streptavidin–APC and detected on the FL-4 channel (emission maximum 660 nm). Total endogenous GFP was detected on the FL-1 channel
(emission maximum 509 nm). CHO cells were either nontransfected (CHO) or CHO cells expressing siglec-7 (S7), siglec-8 (S8), siglec-9 (S9), BACE, JAM-B, or JAM-C.
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Glycan arrays provide a powerful miniaturized system to screen
binding speciﬁcity of putative glycan-binding proteins against
hundreds of different glycan structures [9,29]. In this validation
study, we selected six lipid-linked sialylated glycans shown previ-
ously to be differentially recognized by siglecs-7, -8, and -9 [24]. Todemonstrate binding of the soluble cleaved siglecs to glycan arrays,
it was necessary to increase their avidities by precomplexing in
solution, because monomeric siglecs exhibit very weak afﬁnities,
usually in the high-micromolar to low-millimolar range [30–32].
This was achieved by mixing biotinylated siglec–EGFP proteins
with rabbit anti-GFP and streptavidin–AlexaFluor-647. As shown
in Fig. 4C, each siglec fusion protein gave the predicted binding
Fig.3. Binding of polymeric glycan probes to siglec-expressing CHO cells. Either nontransfected control cells (CHO) or CHO cells expressing siglec-7 (S7), siglec-8 (S8), or
siglec-9 (S9) were incubated with biotinylated PAA probes carrying either lactose, Sia2,8Sia, SLex, or 60SU-SLex and binding detected with streptavidin–APC. See Table 1 for
carbohydrate sequences.
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lecs fused to the Fc region of human IgG1 [24].
To investigate the potential for measuring interactions of pro-
teins with glycosaminoglycans, we generated soluble biotinylated
BACE–EGFP and FGF-1–EGFP fusion proteins and measured bind-
ing to immobilized heparan sulfate 8mer saccharides from porcine
mucosal heparin (Fig. 5). Because of the relatively high afﬁnity of
BACE and FGF-1 for heparin [33,34], it was not necessary to pre-
complex the proteins prior to incubating with the arrays. Both bio-
tin–BACE–EGFP and biotin–FGF-1–EGFP fusion proteins showed a
saccharide dose-dependent increase in binding, whereas biotinyla-
ted siglec-9–EGFP served as negative control and exhibited negligi-
ble binding over the same concentration range. This pattern of
binding of the recombinant proteins was comparable to that seen
previously using commercially available FGF-1 (data not shown)
binding to heparan sulfate saccharide microarrays [35].Protein–protein binding interactions
Having established the utility of the expression system to mea-
sure protein–glycan interactions, we next asked whether we could
also measure weak protein–protein interactions. As a model sys-
tem, we focused on JAM-B and JAM-C, which are thought to be a
heterotypic pair of type 1 membrane cell adhesion molecules ex-
pressed on endothelial cells and some leukocytes [36]. JAMs are
localized at intercellular contacts, where they participate in the
assembly and maintenance of junctions, signaling to cytoskele-
ton-associated proteins, and recruiting cell polarity proteins to
the junctions [37]. Three approaches were used to analyzeinteractions between JAM-B and JAM-C: cell-to-cell, protein-to-
cell, and protein-to-protein binding assays.
For cell-to-cell binding assays, nontransfected CHO cells or
CHO cells expressing either JAM-B or JAM-C were ﬂuorescently
labeled with either DiI (red) or DiD (far red) molecular dye, and
after mixing in a 1:1 ratio and pelleting, the formation of mixed
doublets was assessed by ﬂow cytometry (Fig. 6). This clearly
demonstrated that CHO cells expressing either JAM-B or JAM-C
formed mostly mixed cell doublets rather than cell doublets
expressing only JAM-B or JAM-C (Fig. 6). The binding speciﬁcity
was further demonstrated in protein-to-cell binding assays, in
which biotinylated JAM-B–EGFP or JAM-C–EGFP fusion proteins
(Fig. 7A) were precomplexed with streptavidin–APC and incu-
bated with CHO cells expressing either protein and binding mea-
sured by ﬂow cytometry (Fig. 7B, C). Finally, we explored the use
of soluble cleaved proteins in protein-to-protein binding assays
using surface plasmon resonance (Fig. 8). Biacore streptavidin
chips were derivatized with biotin–JAM-B–EGFP or biotin–JAM-
C–EGFP and probed with the same proteins that had been
precomplexed with anti-GFP Ab. The sensorgrams show a sharp
increase in response units at the beginning of the injection period
and a decrease at the end that represents a background effect due
to the difference in the refractive indexes of the running and sam-
ple buffers (data not shown). A continued slow increase in bind-
ing was seen only when precomplexed JAM-B interacted with
immobilized JAM-C and vice versa (Fig. 8). At the end of the injec-
tion period, this was followed by a gradual decline, indicating
slow dissociation of JAM-B/JAM-C complexes. These results
clearly show the selective binding of JAM-B to JAM-C and vice
versa.
Fig.4. Preparation of soluble siglecs and protein–glycan interactions measured on glycan arrays. (A) Western blot of soluble material released from siglec-expressing CHO
cells either treated (+) or not treated () with PP. Supernatants containing cleaved siglec-7–EGFP (S7), siglec-8–EGFP (S8), and siglec-9–EGFP (S9) were probed with
biotinylated goat anti-GFP followed by streptavidin–alkaline phosphatase. (B) Western blot of cleaved material either pretreated (+) or not pretreated () with BirA enzyme
and probed with streptavidin–alkaline phosphatase. (C) Dose–response microarray analysis of the binding of siglecs to lipid-linked oligosaccharide probes. Microarrays of six
oligosaccharide probes (structures are shown in Table 1) were generated on nitrocellulose-coated glass slides. Each probe was printed in duplicate at 1 ( ), 1.33 ( ), 1.66 ( ),
2.33 ( ), 3.33 ( ), and 5 ( ) fmol/spot. Binding of biotinylated siglec-7–EGFP (top panel), siglec-8–EGFP (middle panel), and siglec-9–EGFP (bottom panel) chimeras was
detected with AlexaFluor-647-labeled streptavidin as described in Materials and methods.
Fig.5. Measurement of protein–glycosaminoglycan interactions. Here 8mer saccharides derived from a partial heparinase I digestion of porcine mucosal heparin were
spotted at different concentrations onto GAPS II microarray slides and incubated sequentially with 20 nM biotinylated protein–EGFP followed by AlexaFluor-546-labeled
streptavidin. (A) Microarray image showing duplicate spots representative of 10 replicate spots. Contrast and brightness has been adjusted to show spot signal with respect to
equivalent background signal. S9, siglec-9; , streptavidin detection reagent applied to subarrays where no protein was incubated. (B) Graphs showing mean spot intensities
against saccharide spotting concentration for different proteins. Spot intensity was normalized relative to background intensity by subtraction of the local background for
each spot and the mean standard deviation of these values calculated for 10 replicate spots.
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A major interest of our group is to understand the biological
roles of protein–glycan interactions. To date, there has been no
systematic attempt to deﬁne the full repertoire of glycan-binding
proteins at a proteomic scale in mammals. The purpose of the cur-
rent study was to design a high-throughput cloning and expressionsystem that was tailored around this goal, with a focus on mem-
brane and secreted proteins. It was felt at the outset that having
both cell-expressed and soluble forms of proteins would be impor-
tant to maximize the chances of detecting very weak interactions
that depend on clustering to achieve the high avidity required for
stable binding. In the case of soluble proteins, the stoichiometry
and spatial organization of multimeric complexes might not
Fig.6. Measurement of protein–protein interactions via cell–cell binding assays. (A) CHO cells, either nontransfected (CHO) or expressing JAM-B or JAM-C, were labeled with
either DiI or DiD molecular dye and mixed together in a 1:1 ratio. After incubation on ice for 60 min, the formation of doublets containing one cell of each type was evaluated
by ﬂow cytometry. (B) Results pooled from ﬁve experiments. Data represent means ± standard errors.
Fig.7. Binding of biotinylated JAM-B–EGFP and JAM-C–EGFP chimeras to CHO cells expressing JAM-B and JAM-C. (A) Western blot of biotinylated JAM-C or JAM-B probed
with streptavidin–alkaline phosphatase shows the presence of a single species for each protein at the expected molecular weight. (B) Wild-type CHO cells (black line) or CHO
cells expressing JAM-B (red and green lines) were incubated with either biotinylated JAM-C–EGFP (black and green lines) or biotinylated JAM-B–EGFP (red line) at 1 lg/ml.
Binding was detected with streptavidin–APC, and cells were analyzed by ﬂow cytometry. (C) Wild-type CHO cells (black line) or CHO cells expressing JAM-C (red and green
lines) were incubated with either biotinylated JAM-B–EGFP (black and green lines) or biotinylated JAM-C–EGFP (red line). Binding was detected with streptavidin–APC, and
cells were analyzed by ﬂow cytometry. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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clustered ligands, whereas the same protein expressed at the cell
surface could achieve this. For example, previous work showed
that a cell-expressed form of the SIGN-R1 lectin can bind its poly-
valent ligand dextran, whereas a recombinant soluble protein can-
not do so even after precomplexing in solution [38].
To express proteins at the cell surface in a form suitable for mul-
tivalent glycan binding, our approach was to employ a GPI anchor
that was fused at the C-terminal position of extracellular regions
of interest. GPI-anchored proteins are efﬁciently transported fromthe Golgi to the outer leaﬂet of the plasma membrane, where they
can undergo lateral diffusion and ligand-induced clustering [13].
GPI anchors can also direct proteins to cholesterol- and sphingo-
lipid-enriched plasmamembranemicrodomains (lipid rafts), where
they are also clustered. In this study, we used the GPI anchor signal
sequence from the TRAIL-R3 protein, which has been shown to tar-
get reporter molecules to non-raft microdomains [12]. Thus, a com-
mon GPI anchor could direct a range of diverse proteins to the cell
surface, making them available for ligand binding as well as for
cleavage and conversion to soluble proteins.
Fig.8. Analysis of interactions between JAM-B and JAM-C by surface plasmon resonance. Biotin–EGFP–JAM-B or biotin–EGFP–JAM-C was immobilized on streptavidin-coated
Biacore chips. EGFP–JAM-B and EGFP–JAM-C were precomplexed with anti-GFP Ab and passed over the Biacore chips for 12 min before switching to buffer alone.
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throughput methodologies [16]. The destination vector we de-
signed incorporates a number of features that both enable rapid
selection of stably expressing cell lines and act as versatile tags
to enable a range of binding assays. These include an EGFP tag that
can be detected by its endogenous ﬂuorescence or with speciﬁc
Abs, a biotinylation motif, a PP cleavage site for optional generation
of soluble proteins, and a GPI anchor signal sequence to direct efﬁ-
cient surface expression. Essentially, the destination vector allows
expression of any peptide sequence containing its own leader pep-
tide such as type 1 membrane proteins and secreted proteins. In
the future, the destination vector could be modiﬁed to include a
leader peptide that would allow expression and screening of other
proteins lacking N-terminal leader peptides, including type II
membrane proteins such as C-type lectins in which the reversed
topology of the protein would still permit interactions with ligands
[39]. A major feature of the current system is that both cell-ex-
pressed and soluble versions of the protein of interest can be gen-
erated from a single vector. This greatly reduces the amount of
work required to generate each form, and although yields of solu-
ble protein are relatively small compared with dedicated expres-
sion platforms, they are more than adequate for microscale
screening of the types described here, including glycan arrays, ﬂow
cytometry, and surface plasmon resonance.
The methodologies established here lend themselves very
favorably to large-scale genome-wide screening of membrane
and secreted proteins for glycan interactions. By using the com-
pleted mammalian gene collection or commercial cDNAs as tem-
plates, preparation of hundreds of membrane and secreted
proteins could be readily achieved [6]. Cell-expressed proteins
could be screened either by using existing libraries of PAA–glycans
[28] or by overlaying cells directly onto glycan arrays (unpublished
observations). Using soluble proteins, the method of choice would
be the glycan arrays with hundreds of immobilized probes, and the
PAA libraries could be analyzed with immobilized soluble proteins.
The same set of proteins could also be analyzed for protein–protein
interactions. This could be achieved by analyzing cellular interac-
tions with other cells or soluble proteins by ﬂow cytometry, as
demonstrated here, or by using cleaved soluble proteins. Here we
demonstrated speciﬁc molecular interactions between JAM-B and
JAM-C by surface plasmon resonance, but high-throughput screen-
ing of protein–protein interactions could be performed using pro-
tein microarrays that require only small amounts of material
[40]. One advantage of the current system over recently described
methods for analyzing protein–protein interaction networks of
extracellular proteins [41] is that both cell-based and soluble pro-
tein-based methods can be used, thereby reducing the chances of
missing important protein recognition due to protein misfolding
or steric hindrance.
In conclusion, the combination of high-throughput protein
cloning and expression technology combined with glycan andprotein array technology provides new opportunities to discover
novel molecular interactions of membrane and secreted proteins.
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